Estão abertas as submissões.
O que acha de publicar seu resumo na revista Cytotherapy????
Então comece a escrever seu resumo, seguem abaixo as instruções:
XI Brazilian Association of Cell and Gene Therapy (ABTCel-Gen) Meeting Abstract Submission Now Open
SUBMISSION DEADLINE: FEBRUARY 8TH, 2021
Why submit your abstract(s) to XI ABTCel-Gen Meeting?
Global networking: Discuss your research with global leaders in basic and translational science
Publish your work: Accepted abstracts will be published in a special supplement of Cytotherapy.
Present your research: Authors of outstanding abstracts will have the opportunity for LIVE Oral Abstracts to present their research at the Meeting.
The Oral Abstract Award
First place in an oral presentation (USD 750).
Second place in an oral presentation (USD 500).
Third place in an oral presentation (USD 250).
Best Poster Award
First place in a poster presentation (USD 500).
Second place in a poster presentation (USD 250).
Third place in a poster presentation (USD 100).
CALL FOR ABSTRACTS
The ABTCel-Gen invites the submission of abstracts that report new research developments.
Start of the submission period: January 5th, 2021.
Deadline for abstract submission: February 8th, 2021.
Notification of approved abstracted: March 1st, 2021.
Notification of abstracts selected for oral presentation and schedule of presentations: March 15th, 2021.
Award Session: May 1st, 2021 (12:45 to 1:00 pm)
Stem cells basic research
Stem cells pre-clinical studies
Stem cells clinical studies
Gene Therapy basic research
Gene Therapy pre-clinical studies
Gene Therapy clinical studies
Stem cells and Dentistry
Stem cells and Veterinary Medicine.
GUIDELINES FOR AUTHORS IN PREPARING ABSTRACTS (CONTENT AND FORMATTING)
- Registration for the meeting is a requirement for abstract submission.
- All abstracts must be written in English.
- The title should be in capitals. Titles are limited to 250 characters, including spaces. Use a short, specific title. Abstract title should be formatted in a sentence case.
Ex: INTRA ARTICULAR INJECTION OF AUTOLOGOUS BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS IN PATIENTS WITH MODERATE TO SEVERE OSTEOARTHRITIS
- Each abstract may indicate only one presenter. The presenter should be the First Author.
Every author should be listed with initials (with punctuation) and last name. If the presenting/corresponding author is to be identified, indicate this author with an asterisk.
Author affiliations: Number each affiliation and list them in sentence case for every author. If an author has multiple affiliations, indicate the numbers for each.
Ex: SP Chin¹,²*, NN Wazir³, CY Cheok¹, CY Wong¹, KY Then¹, SK Cheong¹
¹Mawar Hospital, Negeri Sembilan, Malaysia,
²Beverly Wilshire Medical Centre, Kuala Lumpur, Malaysia,
³International Medical University, Negeri Sembilan, Malaysia,
- The abstract should be structured in paragraphs as follows: background/objective; methods, results, and conclusions. The abstract body cannot exceed 2500 characters, exclusive of the title, author block. Please, do not include figures, tables, and references.
Ex: Background: Bone marrow-derived mesenchymal stromal cells (BMMSC) can be expanded ex vivo, which have the ability to regenerate cartilage for accelerated healing of the knee as demonstrated by animal studies and early clinical reports. In this study we have evaluated the safety and feasibility of using autologous BMMSC as an intra-articular injection for the treatment of symptomatic moderate to severe osteoarthritis.
Methods: Fifteen patients with symptomatic moderate to severe knee osteoarthritis were recruited. All patients have persistent non-improving or deteriorating pain despite regular oral analgesics and multiple hyaluronic injections. Autologous BMMSC was resuspended in a mixture of hyaluronic acid and autologous platelet rich plasma before intra-articular injection procedure. Patients were assessed and followed-up using the Oxford Knee Score (OKS) and magnetic resonance imaging (MRI) for up to 12 months.
Results: The mean OKS at 6 and 12 months after BMMSC injection increased significantly. At 12 months, an improvement of OKS of 4 points or more was observed in 10 patients when compare to their baseline scores for both knees while 2 patients experienced improvement in the right knee only. MRI at12 months post-BMMSC treatment showed noticeable improvement in 60%of patients including mean increase in cartilage thickness from baseline, resolution of subchondral cysts and reduction of effusion.
Conclusion: Autologous BMMSC injection is safe, feasible and may be beneficial for the symptomatic treatment of patients with moderate to severe osteoarthritis who have failed conventional treatment.
- Use standard abbreviations for measuring units; other abbreviations should be spelled out in full at first mention, followed by the abbreviation in parentheses.
- Be sure to proofread your work carefully before submitting it. It is the author’s responsibility to submit a correct abstract; any errors in spelling, grammar, or scientific fact will be published as typed by the author.
- Abstracts must be submitted via the online Abstract Submission System. Abstracts will NOT be accepted by email, mail, or fax.
- Accepted abstracts will be published in a supplemental version of Cytotherapy, the official journal of ISCT.
- There are no fees associated with submitting an abstract.
- Embargo* Policy:
For the abstract to be eligible for presentation at the XI ABTCel-Gen Meeting, the information contained within, as well as additional data and information to be presented about the content, may not be published elsewhere or made public before the abstract has been published/presented at the XI ABTCel-Gen Meeting.
Authors must notify XI ABTCel-Gen Meeting if, after the submission deadline, the submitted abstract is accepted for publication elsewhere and will be published before the XI ABTCel-Gen Meeting. Publication before the meeting may result in the abstract being removed from the conference.
If the Embargo Policy is violated, the abstract may be withdrawn by XI ABTCel-Gen Meeting from the XI ABTCel-Gen Meeting presentation and publication in the abstract supplement.
*An embargo means that information from any abstract or presentation may not be announced, publicized, or distributed before the embargo date and time.
Please review and gather all information before you starting the submission process using the Online Abstract Submission System.
All abstracts selected will be presented in the poster section.
The six (6) best abstracts will be chosen for oral presentation.
RICARDO RIBEIRO DOS SANTOS AWARD:
First place in an oral presentation (USD 600).
Second place in an oral presentation (USD 400).
Third place in an oral presentation (USD 200).
JULIO VOLTARELLI AWARD:
First place in a poster presentation (USD 400).
Second place in a poster presentation (USD 200).
Third place in a poster presentation (USD 100).
To compete for the awards, the first author (presenter) must be an undergraduate / graduate student or have received their last degree from 2015.
Oral presentations are limited to 10 minutes for presentation and 5 minutes for discussion. The selected authors should prepare presentation media in English and sufficiently clear to be viewed online. The file should be sent to the XI ABTCel-Gen Meeting by April 24th, 2021.